The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 36.00
Bid: 35.50
Ask: 36.50
Change: 0.00 (0.00%)
Spread: 1.00 (2.817%)
Open: 36.00
High: 35.50
Low: 35.50
Prev. Close: 36.00
CREO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of General Meeting

1 Aug 2018 13:24

RNS Number : 5083W
Creo Medical Group PLC
01 August 2018
 

1 August 2018

Creo Medical Group plc

("Creo" or the "Company")

 

Result of General Meeting

 

Creo Medical Group plc (AIM: CREO) is pleased to announce that, at the General Meeting held today, all resolutions were duly passed by means of a poll vote. The total number of votes received for each resolution is set out below:

 

Resolution No.

Votes for

Votes against

Votes total

Votes withheld

01

63,639,528 (94.09%)

 

3,995,278 (5.91%)

67,634,806 (83.37%)

625,000

02

63,639,528 (94.09%)

 

3,995,278 (5.91%)

67,634,806 (83.37%)

625,000

03

63,639,528 (93.23%)

4,620,278 (6.77%)

68,259,806 (84.14%)

 

0

 

The Company confirms that, conditional on Admission becoming effective, it has allotted and issued 4,000,000 new Ordinary Shares pursuant to the EIS/VCT Placing. It is expected that the EIS/VCT Placing Shares will be admitted to AIM with effect from 8.00am tomorrow, 2 August 2018.

 

Further details regarding the Placing and the Placing Shares can be found in the announcement issued by the Company on 13 July 2018 and in the Circular posted to Shareholders on that same day, which are available to view on the Company's website: investors.creomedical.com. Capitalised terms used, but not defined, in this announcement shall have the same meaning as set out in the Circular.

 

Following Admission of the EIS/VCT Placing Shares, the Company's issued ordinary share capital will consist of 85,123,065 Ordinary Shares; no shares are held in treasury. The above figure of 85,123,065 Ordinary Shares may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the voting rights of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

The Additional EIS/VCT Placing is conditional on receipt of the Additional VCT Advanced assurance by the Company. Whilst the Non EIS/VCT Placing is not conditional the receipt of the Additional VCT Advanced Assurance, the allotment and Admission of the Non EIS/VCT Shares cannot take place before the allotment of the Additional EIS/VCT Shares.

 

As the Additional VCT Advanced Assurance has not yet been obtained, the issue of the Additional EIS/VCT Shares and the Non EIS/VCT Shares has been delayed. Admission of the Additional EIS/VCT Shares and Non EIS/VCT Shares will occur on the third Business Day following receipt of Additional VCT Advanced Assurance.

 

In the event that the Additional VCT Advanced Assurance is not received before the Long Stop Date of 13 September 2018 (or at such time as HMRC has informed the Company that such approval will not be obtained), then the Additional EIS/VCT Placing will not complete, but the Non EIS/VCT Placing will complete, the Non EIS/VCT Shares will be issued and Admission of the Non EIS/VCT Shares will take place at latest on the Long Stop Date.

 

Contacts

 

Creo Medical:

+44 (0)129 160 6005

Richard Rees

Cenkos:

+44 (0)207 397 8900

Camilla Hume / Mark Connelly (NOMAD)

Michael Johnson / Russell Kerr (Sales)

FTI Consulting:

+44 (0)203 727 1000

Brett Pollard / Mo Noonan

creo@fticonsulting.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ROMSSEFEFFASEEA
Date   Source Headline
12th Nov 20217:00 amRNSAcquisition of Aber Electronics Limited
11th Nov 20217:00 amRNSAppointment of Joint Broker
30th Sep 202112:00 pmRNSTotal Voting Rights
30th Sep 20217:00 amRNSHalf-year Report
9th Sep 202111:23 amRNSDirector/PDMR Shareholding
8th Sep 20213:59 pmRNSHolding(s) in Company
16th Aug 20213:34 pmRNSOpen Offer Launch, Posting of Circular & GM Notice
13th Aug 20214:45 pmRNSResult of Placing
12th Aug 20215:37 pmRNSProposed Placing & Open Offer, Launch of ABB
30th Jul 20215:00 pmRNSTotal Voting Rights
20th Jul 20213:42 pmRNSShare Awards, Director Dealings & Issue of Equity
16th Jul 20217:00 amRNSOpening of United States East Coast Headquarters
1st Jul 20218:00 amRNSIssue of Equity
30th Jun 202110:30 amRNSResult of AGM
16th Jun 20217:00 amRNSMicroBlate Fine’s first in-human use update
14th Jun 20217:00 amRNSAcquisition of freehold site for £4.25m
4th Jun 20217:01 amRNSNotice of AGM
4th Jun 20217:00 amRNSFinal Results
26th May 20217:00 amRNSFurther health economics data validates technology
19th May 20217:00 amRNSTrading Update
30th Apr 20217:00 amRNSTotal Voting Rights
19th Apr 20217:00 amRNSExercise of Options
19th Feb 202111:31 amRNSHolding(s) in Company
17th Feb 20217:00 amRNSTrading update
7th Jan 20217:00 amRNSUS FDA clearance for MicroBlate™ Flex device
9th Dec 202011:06 amRNSSecond Price Monitoring Extn
9th Dec 202011:00 amRNSPrice Monitoring Extension
9th Dec 20207:00 amRNSFirst clinical use of new Creo GI product
24th Nov 20201:36 pmRNSExercise of Options
3rd Nov 20207:00 amRNSAcquisition of Boucart Medical SRL
2nd Nov 20207:00 amRNSUS FDA clearance for MicroBlate™ Fine device
23rd Sep 20207:00 amRNSHalf-year Report
26th Aug 20204:09 pmRNSHolding(s) in Company
11th Aug 20207:00 amRNSExercise of Options
3rd Aug 20207:00 amRNSVideo abstract published endorsing Speedboat
24th Jul 202011:00 amRNSDirector/PDMR Shareholding
24th Jul 20207:00 amRNSAcquisition of Albyn Medical S.L.
13th Jul 202010:37 amRNSSecretary of State for Wales site visit
13th Jul 202010:08 amRNSSecretary of State for Wales site visit
6th Jul 20207:00 amRNSDirectorate Change
2nd Jul 20207:00 amRNSDevelopment loan for plasma sterilising product
24th Jun 202010:30 amRNSResult of AGM
15th Jun 20207:00 amRNSCE mark for five new devices
8th Jun 20207:00 amRNSIET Prize nomination
3rd Jun 20207:00 amRNSPositive NHS health economics data
27th May 20207:00 amRNSPosting of Annual Report & Notice of AGM
20th May 20207:00 amRNSCommercialisation Agreement
7th May 20207:00 amRNSFinal Results
23rd Mar 20207:00 amRNSFDA Clearance for HS1 Haemostasis Device
20th Mar 20207:00 amRNSTrading update – COVID-19 impact

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.